NEW YORK (GenomeWeb) – Genomics England said today that it has enlisted a startup maker of artificial intelligence in a long-term partnership meant to increase patient access to immunotherapies, monitor treatment effectiveness, and identify resistance to these advanced cancer drugs.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.